INFLUENCE OF METABOLIC SYNDROME ON LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

Authors

  • Rustamov U.M. Andijan State Medical Institute, 170100, Uzbekistan, Andijan, Atabekova st.1 Author
  • Azimova S.B. Tashkent State Medical University, 100109 Tashkent, Uzbekistan, 2 Farobiy Street, Author

Keywords:

benign prostatic hyperplasia, lower urinary tract symptoms, metabolic syndrome, International Prostate Symptom Score, prostate-specific antigen, obesity, dyslipidemia, insulin resistance, prostate volume, inflammation.

Abstract

Lower urinary tract symptoms (LUTS) represent one of the most common clinical manifestations of benign prostatic hyperplasia (BPH) and significantly impair quality of life among aging men. Although benign prostatic enlargement has traditionally been considered the principal cause of LUTS, growing evidence indicates that systemic metabolic abnormalities also contribute substantially to the pathogenesis and progression of urinary symptoms. Metabolic syndrome, characterized by central obesity, impaired glucose metabolism, dyslipidemia, and arterial hypertension, has been increasingly recognized as an important factor influencing prostatic growth, chronic inflammation, autonomic nervous system activity, and bladder function. These metabolic alterations may accelerate the development of LUTS through endothelial dysfunction, oxidative stress, insulin resistance, and hormonal imbalance. The present study aimed to evaluate the influence of metabolic syndrome on lower urinary tract symptoms in patients with benign prostatic hyperplasia by analyzing clinical, anthropometric, and biochemical characteristics. The study included patients diagnosed with BPH with and without metabolic syndrome, together with an age-matched healthy control group. Clinical evaluation comprised body mass index, waist circumference, systolic and diastolic blood pressure, fasting plasma glucose, serum triglycerides, high-density lipoprotein cholesterol, prostate-specific antigen (PSA), prostate volume measured by transrectal ultrasonography, and the severity of lower urinary tract symptoms assessed using the International Prostate Symptom Score (IPSS). The findings demonstrated that patients with metabolic syndrome exhibited significantly more severe lower urinary tract symptoms, accompanied by increased prostate volume, higher PSA concentrations, and more pronounced metabolic abnormalities than patients without metabolic syndrome. Furthermore, the severity of LUTS was positively associated with obesity, hyperglycemia, hypertriglyceridemia, and enlarged prostate volume, whereas HDL cholesterol showed an inverse relationship with symptom severity. These findings suggest that metabolic syndrome contributes to the progression of lower urinary tract symptoms in patients with benign prostatic hyperplasia and should be considered during clinical evaluation and individualized therapeutic management.

References

1.European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms (LUTS), including Benign Prostatic Obstruction. Arnhem, The Netherlands: European Association of Urology; 2025.

2.European Association of Urology. EAU Guidelines on Management of Non-metastatic Prostate Cancer. Arnhem, The Netherlands; 2025.

3.American Urological Association. Benign Prostatic Hyperplasia (BPH) Guideline. American Urological Association. 2023.

4.International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels: International Diabetes Federation; Updated guidance.

5.Ng MCF, Lee JY, Wong SYS, et al. Metabolic syndrome and lower urinary tract symptoms: A systematic review and meta-analysis. World Journal of Urology. 2022;40(8):1969–1981.

6.Gacci M, Sebastianelli A, Salvi M, et al. Metabolic syndrome and benign prostatic enlargement: Current evidence and clinical implications. Current Opinion in Urology. 2021;31(1):1–8.

7.Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nature Reviews Urology. 2021;18(2):108–119.

8.Corona G, Vignozzi L, Rastrelli G, et al. Benign prostatic hyperplasia: A new metabolic disease? Journal of Endocrinological Investigation. 2020;43(9):1209–1229.

9.De Nunzio C, Presicce F, Tubaro A. Metabolic syndrome and benign prostatic enlargement: Pathophysiological links and clinical perspectives. Prostate Cancer and Prostatic Diseases. 2022;25(2):246–254.

10.Parsons JK. Lifestyle factors, metabolic syndrome and benign prostatic hyperplasia. Current Opinion in Urology. 2021;31(1):23–28.

11.Roehrborn CG. Pathophysiology of benign prostatic hyperplasia and lower urinary tract symptoms: Recent advances. Urology. 2022;163:3–10.

12.Gravas S, Cornu JN, Gacci M, et al. Current concepts in the evaluation and management of male lower urinary tract symptoms. European Urology. 2023;84(2):165–178.

13.Wang Y, Liu X, Zhang Y, et al. Association between metabolic syndrome and lower urinary tract symptoms: Evidence from a systematic review and meta-analysis. Frontiers in Endocrinology. 2023;14:1187421.

14.Kwon H, Kang SH, Lee JG, et al. Impact of obesity and metabolic syndrome on lower urinary tract symptoms in aging men. International Neurourology Journal. 2021;25(3):177–186.

15.Yassin AA, Nettleship JE, Almehmadi Y, et al. Metabolic syndrome, testosterone deficiency and benign prostatic hyperplasia: Clinical interactions and therapeutic implications. Arab Journal of Urology. 2021;19(2):133–144.

16.Cantiello F, Cicione A, Autorino R, et al. Obesity, insulin resistance and lower urinary tract symptoms: Clinical evidence and biological mechanisms. International Journal of Molecular Sciences. 2022;23(15):8397.

17.Rastrelli G, Vignozzi L, Maggi M. Chronic inflammation, metabolic syndrome and benign prostatic hyperplasia: Emerging evidence. International Journal of Molecular Sciences. 2023;24(6):5608.

18.Shariat SF, Roehrborn CG, Karakiewicz PI, et al. Biomarkers and clinical predictors of lower urinary tract symptoms in men with benign prostatic hyperplasia. European Urology Focus. 2022;8(4):1065–1074.

Downloads

Published

2026-07-16